SAN DIEGO, CA -- (Marketwired) -- 06/23/14 --
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is excited to announce the release of a next generation monitoring platform with computer-assisted surgery applications to enhance both speed and efficiency.
Core to the NuVasive philosophy of facilitating reproducible outcomes in spine surgery is the procedural integration of neurophysiology and computer-assisted surgery technologies. The recently released NVM5® V2.0 hosts a comprehensive set of intraoperative technologies specifically designed for spine surgery, including the sensory monitoring modality (SSEP) for multimodality monitoring of the spinal cord and peripheral nerves, as well as refinements to the recently launched spinal rod-bending technology called Bendini®.
NVM5 V2.0 leverages the experience that NuVasive has accumulated through the past 12 years, with more than 250,000 spine surgeries utilizing the Company's proprietary monitoring platform.
Capabilities of the NVM5® platform in spine surgery include:
- Nerve avoidance during an XLIF procedure in order to navigate the psoas
- Nerve proximity information during pedicle cannulation and screw placement
- Computer-assisted, rod-bending technology
- Nerve root monitoring
- Spinal cord monitoring
- Peripheral sensory nerve monitoring
Pat Miles, NuVasive President of Global Products and Services, said, "NVM5 Version 2.0 demonstrates our continued commitment to developing innovative, adjunctive technologies that assist in the safety and reproducibility of surgical outcomes for spine patients, while also improving operating room economics."
About the NVM5 System:
The NVM5 System is a medical device that is intended for intraoperative neurophysiologic monitoring during spinal surgery. The device provides information directly to the surgeon, to help assess a patient's neurophysiologic status. NVM5 provides this information by electrically stimulating nerves via electrodes located on surgical accessories and monitoring electromyography (EMG), transcranial motor evoked potential (TcMEP), or somatosensory evoked potential (SSEP) responses of nerves. The System also integrates Bendini software used to locate spinal implant instrumentation for the placement of spinal rods.
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.7 billion global spine market.
NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS®, platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company's dedication to innovation continues to spawn game-changing technology such as the XLIF Decade™ plate for single-approach fixation through a lateral incision, the PCM® motion-preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and the Armada® posterior fixation system, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedurally integrated solutions that completely redefine and improve upon traditional techniques like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation, and Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's minimally disruptive surgical products by spine surgeons, development and acceptance of new products or product enhancements, our ability to effectually manage inventory as we continue to release new products, and the other risks and uncertainties described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Source: NuVasive, Inc.